NASDAQ:LPCN Lipocine (LPCN) Stock Price, News & Analysis $3.34 +0.05 (+1.36%) Closing price 03:58 PM EasternExtended Trading$3.23 -0.11 (-3.35%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lipocine Stock (NASDAQ:LPCN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lipocine alerts:Sign Up Key Stats Today's Range$3.23▼$3.6050-Day Range$2.83▼$3.6852-Week Range$2.75▼$11.79Volume10,352 shsAverage Volume31,746 shsMarket Capitalization$17.90 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingBuy Company OverviewLipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.Read More… Lipocine Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreLPCN MarketRank™: Lipocine scored higher than 48% of companies evaluated by MarketBeat, and ranked 549th out of 912 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingLipocine has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageLipocine has received no research coverage in the past 90 days.Read more about Lipocine's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Lipocine is -4.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lipocine is -4.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLipocine has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Lipocine's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.39% of the float of Lipocine has been sold short.Short Interest Ratio / Days to CoverLipocine has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lipocine has recently decreased by 5.89%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLipocine does not currently pay a dividend.Dividend GrowthLipocine does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.39% of the float of Lipocine has been sold short.Short Interest Ratio / Days to CoverLipocine has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lipocine has recently decreased by 5.89%, indicating that investor sentiment is improving significantly. News and Social Media1.8 / 5News Sentiment0.29 News SentimentLipocine has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Lipocine this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lipocine insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.12% of the stock of Lipocine is held by insiders.Percentage Held by InstitutionsOnly 9.11% of the stock of Lipocine is held by institutions.Read more about Lipocine's insider trading history. Receive LPCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter. Email Address LPCN Stock News HeadlinesLipocine Reports Q1 2025 Financial ResultsMay 8 at 10:16 AM | tipranks.comLipocine Announces Financial Results for the First Quarter Ended March 31, 2025May 8 at 8:00 AM | prnewswire.comAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.May 8, 2025 | Paradigm Press (Ad)Lipocine inks license and supply agreement for TLANDO in BrazilMay 7 at 1:42 AM | msn.comLipocine s’associe à Aché pour commercialiser TLANDO au BrésilMay 7 at 1:42 AM | fr.investing.comLipocine Partners with Aché for TLANDO® in BrazilMay 6 at 10:21 AM | tipranks.comLipocine Announces License and Supply Agreement for TLANDO® in BrazilMay 6 at 8:00 AM | prnewswire.comLipocine (NASDAQ:LPCN) Earns Hold Rating from Analysts at StockNews.comMay 1, 2025 | americanbankingnews.comSee More Headlines LPCN Stock Analysis - Frequently Asked Questions How have LPCN shares performed this year? Lipocine's stock was trading at $4.88 at the beginning of the year. Since then, LPCN stock has decreased by 31.5% and is now trading at $3.3450. View the best growth stocks for 2025 here. How were Lipocine's earnings last quarter? Lipocine Inc. (NASDAQ:LPCN) posted its quarterly earnings results on Wednesday, May, 7th. The specialty pharmaceutical company reported ($0.35) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.35). The specialty pharmaceutical company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.35 million. When did Lipocine's stock split? Shares of Lipocine reverse split on the morning of Friday, May 12th 2023. The 1-17 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. How do I buy shares of Lipocine? Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lipocine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lipocine investors own include Zomedica (ZOM), Plug Power (PLUG), Workhorse Group (WKHS), Ovid Therapeutics (OVID), FuelCell Energy (FCEL), Fortress Biotech (FBIO) and KALA BIO (KALA). Company Calendar Last Earnings5/07/2025Today5/08/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LPCN CIK1535955 Webwww.lipocine.com Phone(801) 994-7383Fax801-994-7388Employees10Year Founded1997Price Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+199.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,350,000.00 Net MarginsN/A Pretax Margin-51.17% Return on Equity-19.17% Return on Assets-17.60% Debt Debt-to-Equity RatioN/A Current Ratio12.97 Quick Ratio12.97 Sales & Book Value Annual Sales$11.20 million Price / Sales1.60 Cash FlowN/A Price / Cash FlowN/A Book Value$3.83 per share Price / Book0.87Miscellaneous Outstanding Shares5,350,000Free Float5,021,000Market Cap$17.90 million OptionableNo Data Beta1.52 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:LPCN) was last updated on 5/8/2025 by MarketBeat.com Staff From Our PartnersTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredIt may already be too late… A global energy shift is underway—and lithium is at the center of it. From electric vehicles to grid storage a...Huge Alerts | SponsoredTrump's $500B plan is fueling these monthly dividendsSomething extraordinary happened just 24 hours after Trump returned to office... He signed a document that ...Investors Alley | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | Sponsored[FREE GIFT] New AI for retail tradersTradeAlgo has found a “backdoor way” for retail traders to profit from the AI arms race by developing its grou...TradeAlgo | SponsoredBitcoin Just Broke $100K – Are You Positioned?This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipocine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lipocine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.